Evidence map›Paper›PMID 36539610›Full record

ArticleJournal of labelled compounds & radiopharmaceuticals2023

Synthesis and radiolabeling of a polar [

Natasha Bidesi, Vladimir Shalgunov, Umberto Maria Battisti, Lars Hvass, Jesper Tranekjaer Jørgensen, Christian B M Poulie, Andreas I Jensen, Andreas Kjaer, Matthias M Herth

Open access · hybridAbstract read
In one paragraph

Article in Journal of labelled compounds & radiopharmaceuticals, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Synthesis and radiolabeling of a polar [Journal of labelled compounds & radiopharmaceuticals · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Natasha BidesiDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Vladimir ShalgunovDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Umberto Maria BattistiDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID https://orcid.org/0000-0002-1012-8644
Lars HvassDepartment of Clinical Physiology, Nuclear Medicine and PET & Cluster for Molecular Imaging, Copenhagen University Hospital - Rigshospitalet & Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
Jesper Tranekjaer JørgensenDepartment of Clinical Physiology, Nuclear Medicine and PET & Cluster for Molecular Imaging, Copenhagen University Hospital - Rigshospitalet & Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
Christian B M PoulieDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Andreas I JensenCenter for Nuclear Technologies (DTU Nutech), Technical University of Denmark (DTU), Roskilde, Denmark.ORCID https://orcid.org/0000-0002-9085-8603
Andreas KjaerDepartment of Clinical Physiology, Nuclear Medicine and PET & Cluster for Molecular Imaging, Copenhagen University Hospital - Rigshospitalet & Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
Matthias M HerthDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID https://orcid.org/0000-0002-7788-513X
University of Copenhagen · DKTechnical University of Denmark · DK

Funding

European Union's Horizon 2020 813528Innovation Fund DenmarkNovo Nordisk Foundation NNF18SA0034956
6 · The paper itself

Abstract

Pretargeting imaging has gained a lot of prominence, due to its excellent bioorthogonality and improved imaging contrast compared to conventional imaging. A new iodo tetrazine (Tz) derivative has been synthesized and further developed into the corresponding iodine-125 (

Indexed as

Heterocyclic CompoundsRadiopharmaceuticalsAza CompoundsBenzene DerivativesCell Line, TumorClick ChemistryIodine Radioisotopes1,2,4,5-tetrazineAza CompoundsBenzene DerivativesHeterocyclic CompoundsIodine-125Iodine RadioisotopesRadiopharmaceuticalsbioorthogonalclick chemistryidodine-125pretargetingtetrazine

Identifiers

PMID36539610
PMCPMC10107300
OpenAlexW4312033017

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.